Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 21

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 21
---
 behalf, each of the Agents will be deemed to be an “underwriter” within the meaning of the Securities Act, and the
compensation paid to the Agents will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide
indemnification and contribution to the Agents against certain liabilities, including liabilities under the Securities Act. The Agents
will not engage in any transactions that stabilizes our common stock.

Our common stock is currently listed on The Nasdaq
Capital Market and trades under the symbol “DERM.” The transfer agent of our common stock is VStock Transfer, LLC.

The Agents and their respective affiliates have
provided, and may in the future provide, various investment banking and other financial services for us for which services they have received
and, may in the future receive, customary fees.

<div align='center'>S-13

LEGAL MATTERS</div>

The validity of the securities and certain other
matters will be passed upon for us by Troutman Pepper Locke LLP, Charlotte, North Carolina. The Agents are being represented in connection
with this offering by Duane Morris LLP, New York, New York.

<div align='center'>EXPERTS</div>

The consolidated financial statements of Journey Medical Corporation as of December 31, 2024 and 2023 and for each of the years then ended
have been incorporated by reference herein in reliance upon the report of KPMG LLP, an independent registered public accounting firm,
incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering
the December 31, 2024 consolidated financial statements contains an explanatory paragraph that states the Company has suffered recurring
losses from operations, and as a result has concluded that raises substantial doubt about its ability to continue as a going concern.
The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We are a reporting company and file annual, quarterly
and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement on Form S-3
under the Securities Act with respect to the securities we are offering under this prospectus supplement. This prospectus supplement and
the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration
statement. For further information with respect to us and the securities offered under this prospect